OM
NDRM

Opaleye Management’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Opaleye Management’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-70,000
Closed -$2.72M – 49
2017
Q3 		$2.72M Sell
70,000
-50,300
-42% -$1.85M 0.96% 27
2017
Q2 		$3.6M Buy
120,300
+300
+0.3% +$7.77K 1.5% 21
2017
Q1 		$3.19M Buy
120,000
+5,000
+4% +$124K 1.59% 21
2016
Q4 		$1.73M Buy
115,000
+16,500
+17% +$309K 1.02% 31
2016
Q3 		$1.82M Buy
98,500
+46,000
+88% +$797K 0.95% 34
2016
Q2 		$853K Buy
52,500
+14,000
+36% +$236K 0.57% 46
2016
Q1 		$544K Buy
+38,500
New +$520K 0.34% 48
2015
Q3 		– Sell
-26,000
Closed -$399K – 56
2015
Q2 		$399K Buy
+26,000
New +$366K 0.16% 44

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

Opaleye Management's NDRM Position: Q4 2017 in Review

Opaleye Management sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 70,000 shares — an estimated $2.72M sold.

Opaleye Management first reported a position in NDRM in Q2 2015 and held it in 8 quarters. The position peaked at $3.6M in Q2 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • Opaleye Management reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • Opaleye Management sold 70,000 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $2.72M.
  • Opaleye Management first reported a position in NeuroDerm Ltd. Ordinary Shares in Q2 2015 and held it in 8 quarters.
  • Opaleye Management's NeuroDerm Ltd. Ordinary Shares position peaked at $3.6M in Q2 2017.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on Opaleye Management's 13F filing for Q4 2017, filed 9 Feb 2018.